HAYWARD, Calif., July 11, 2011 /PRNewswire/ -- Molecular diagnostics company GenturaDx announced today that Geoffrey A. McKinley, Ph.D., has joined the company as Senior Vice President of Research & Development. McKinley joins as GenturaDx accelerates research to bring its IDbox™ System to commercialization.
"With his depth of experience developing molecular diagnostic products, Geoff will be a key asset in commercializing our molecular platform in the next 12 to 24 months," said Mark Bagnall, GenturaDx's chief executive officer. "GenturaDx anticipates completing beta studies this year and clinical studies in 2012, and Geoff is an important addition to a talented R & D team working to perfect our system as well as develop partnerships with companies that seek to adapt assay content to our platform."
Dr. McKinley brings to GenturaDx nearly two decades of research & development and business development experience related to developing molecular diagnostic products and tools for infectious diseases. Prior to joining GenturaDx, Dr. McKinley was responsible for research & development to support molecular biology assay, consumable and instrumentation development at Osmetech, Inc. He has previously held positions at Naxcor, Inc., BioMerieux, Inc., and Analytab Products, a division of Sherwood Medical. Dr. McKinley earned his Ph.D. at Colorado State University.
"It's a great time to be at GenturaDx," Dr. McKinley said, "because its unique, PCR-based, sample-to-answer IDbox System has the potential to dramatically impact molecular diagnostics, offering potential performance advantages over existing systems on the market and making the molecular testing affordable and easy to use for the estimated 5,000 small-to-medium sized hospitals that rely on traditional culture techniques or immunoassay testing."
GenturaDx is a molecular diagnostic company focused on making molecular diagnostics both affordable and practical for any laboratory to perform. The company's IDbox System incorporates all aspects of proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform reduces the risk of contamination and saves time; the platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test.
Copyright©2010 PR Newswire.
All rights reserved